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Meta-analysis derived atopic dermatitis (MADAD)
transcriptome defines a robust AD signature
highlighting the involvement of atherosclerosis and
lipid metabolism pathways
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Thomas Litman3, Emma Guttman-Yassky1,2 and Mayte Suárez-Fariñas1,2,7,8*
Abstract
Background: Atopic dermatitis (AD) is a common inflammatory skin disease with limited treatment options. Several
microarray experiments have been conducted on lesional/LS and non-lesional/NL AD skin to develop a genomic
disease phenotype. Although these experiments have shed light on disease pathology, inter-study comparisons
reveal large differences in resulting sets of differentially expressed genes (DEGs), limiting the utility of direct
comparisons across studies.
Methods: We carried out a meta-analysis combining 4 published AD datasets to define a robust disease profile,
termed meta-analysis derived AD (MADAD) transcriptome.
Results: This transcriptome enriches key AD pathways more than the individual studies, and associates AD with
novel pathways, such as atherosclerosis signaling (IL-37, selectin E/SELE). We identified wide lipid abnormalities and,
for the first time in vivo, correlated Th2 immune activation with downregulation of key epidermal lipids (FA2H,
FAR2, ELOVL3), emphasizing the role of cytokines on the barrier disruption in AD. Key AD “classifier genes”
discriminate lesional from nonlesional skin, and may evaluate therapeutic responses.
Conclusions: Our meta-analysis provides novel and powerful insights into AD disease pathology, and reinforces the
concept of AD as a systemic disease.
Keywords: Atopic dermatitis, Meta-analysis, Transcriptome, Atherosclerosis, Expression analysis
Background
Atopic dermatitis (AD) is the most common inflammatory
skin disease (4–7 % prevalence in adults, and ~15 % in
children), with a large unmet need for safer and more
effective treatments [1–7]. Immune and barrier abnormal-
ities characterize AD, with Th2/Th22 cytokine activation,
increased hyperplasia and significant decreases in differenti-
ation markers. These observations have led to two compet-
ing pathogenic hypotheses [1, 8, 9], although recent studies
characterizing AD primarily as an immune-driven disease
have shown reversal of barrier defects following specific
and non-specific therapeutic interventions [10–13].
Genomic expression profiling using gene-arrays and
real time (RT)-PCR has been widely used to identify
gene alterations in lesional (LS) and non-lesional (NL)
AD compared to normal skin to better understand inter-
actions between activation of cytokine pathways and
epidermal abnormalities [6, 7, 10, 12, 14, 15]. Similar to
other diseases, the AD phenotype/transcriptome can be
defined genomically by differentially expressed genes
(DEGs) between LS and NL skin [15]. A robust tran-
scriptome was established as a powerful tool in iden-
tifying core psoriasis pathogenesis and evaluating the
efficacy of targeted therapeutics at transcriptomic level
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[16, 17]. The high rates of placebo effect in AD patients
contrasts with a worsening of disease phenotype at the
transcriptomic level [10], reinforcing the importance of a
robust disease transcriptome against which therapeutic
effects can be evaluated [18]. Genomic profiling may
also be used to predict therapeutic responses, as in
juvenile idiopathic arthritis, in which profiling correctly
predicted therapeutic responses at 6 months [19].
Nevertheless, high-throughput genomic analyses are
vulnerable to multiple biases, including random noise,
biological heterogeneity, and differences in experimental
procedures (biopsies, hybridization, etc.), leading to re-
markably little overlap between DEGs in similar scale
studies [20–22]. A meta-analysis approach that com-
bines microarray data from independent yet similarly de-
signed studies allows one to overcome these variations,
ultimately increasing the power and reproducibility of
the transcriptome [23–25]. While several meta-analysis
methods exist for combining microarray data from inde-
pendent studies [26], the random-effects model (REM)
has been established as one of the most suitable for het-
erogeneous studies [25, 27, 28].
We applied a REM meta-analysis model including 4
published AD microarray studies (including 97 samples;
54 LS and 43 NL; 41 paired) to determine core pathogenic
elements and new disease associated genes [9, 10, 12, 15],
resulting in the Meta-Analysis Derived AD (MADAD)
disease transcriptome, a robust active disease signature of
595 DEGs, including 86 that were not previously detected
by any individual study.
Methods
Sample collection
All samples were collected according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [29]. A total of 28 datasets were
detected in Gene Expression Omnibus (GEO), but only
datasets including LS and NL skin samples of AD patients
were retained. Datasets run on platforms other than the
HGU133Plus 2 chip, subject to treatments, or with
non-randomly selected NL or LS samples (e.g. FLG
homozygous/heterozygous loss of function mutation),
and datasets without NL samples were excluded. When
overlapping samples were found between datasets, only
one copy was kept. Four microarray datasets satisfied the
established criteria (GSE32924, GSE36842, GSE58558,
GSE59294) [9, 10, 12, 15], including 97 samples (54 LS
and 43 NL), which coincidently have been carried out by
our group.
Pre-processing and expression analysis
Pre-processing and statistical analyses were performed
using R and Bioconductor packages [30, 31]. Raw expres-
sion data were combined, summarized, and normalized
using GCRMA [32]. Batch effects between datasets were
adjusted for by the empirical Bayes method ComBat/
SVA [32–35]. Agreement of the individual studies raw
microarray data was estimated by the Integrated Cor-
relation Coefficient Analysis, which produces the general
Integrated Correlation Coefficient (ICC), representing
agreement between studies, and can be interpreted in the
same way as Pearson correlation coefficient. The ICC was
used to eliminate background noise prior to the analysis,
by excluding genes with incoherent behavior across
studies [36].
For each study, estimation of differences in expression
levels of LS vs NL skin was performed using the mixed-
effect framework of the limma package.
Meta-analysis
The formal random effects model (REM), described by
Choi [27]. was applied to estimate the true effect size for
each probe (see Additional file 1). These estimation and
calculation steps were performed using the package
GeneMeta. P-values were adjusted for multiple testing
using the Benjamini-Hochberg procedure [37], with cri-
teria for DEGs of absolute fold change (|FCH|) ≥ 2.0 and
a false discovery rate (FDR) ≤ 0.05.
Post-processing
The MADAD transcriptome was subject to multiple
downstream analysis methods. Integration-driven dis-
covery/IDD-DEGs were defined as those not identified
in any of the included studies. To explore functional an-
notations, overrepresentation analysis was carried out
for BP GO-terms and KEGG pathways (both in DAVID)
[38], Ingenuity Pathways (IPA – www.ingenuity.com, as
described) [25], and on previously reported gene-sets [39].
The normalized LS and NL expression data were subject
to Weighted Gene Co-Expression Networks Analysis
(WGCNA) to detect clusters (modules) of correlated
genes and respective hub genes [40]. These modules were
subject to trait correlation and corresponding gene-set
overrepresentation analysis.
Meta Threshold Gradient Directed Regularization
(MTGDR) method [41, 42] was used to select disease-
associated genes while allowing for varied estimates of
those genes across different experiments, as previously
published [41, 42].
Primers and probes were designed for RT-PCR as pre-
viously described (see Additional file 1 and Additional
file 2) [43]. Ribosomal protein, large, P0/RPLP0 normal-
ized RT-PCR expression data was analyzed using a
mixed-effect framework after log2-transformation.
Lipid metabolism genes were defined as genes related to
one of the four groups: Ceramides, Free Fatty Acids,
Sphingolipids, and Cholesteryl Esters in the Gene Cards
database (www.genecards.org). We included all genes with
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a relevance score ≥ 10 [44, 45]. Pairwise Pearson correla-
tions were calculated between the gene and patient
specific deregulations. Multivariate correlations between
sets of genes were calculated making use of the gene set
specific μ-scores calculated by the muStat package [46].
Results
Data collection
Two major repositories (GEO Omnibus and ArrayExpress)
were queried to identify studies with expression profiles
of LS and NL punch biopsies from AD patients. Four
studies (GSE59294, GSE58558, GSE36842, GSE32924;
including 97 samples, with 54 LS and 43 NL, 41 paired)
met all inclusion criteria following the PRISMA guide-
lines (see Methods, Additional file 3: Figure E1 and
Additional file 4: Table E1) [9, 10, 12, 15]. We only used
data from chronic lesions in the analysis. No significant
differences in disease severity (as measured by Scoring
of AD/SCORAD and Eczema Area and Severity/EASI
indices) or IgE levels were found across patients who all
had moderate-to-severe AD (SCORAD> 25; EASI > 12).
Meta-analysis framework
The Venn diagram in Fig. 1a represents the overlap of
DEGs identified by the individual studies, including 25
consensus DEGs (see Additional file 5: Table E2). Be-
sides inter-study variation, sources of inconsistency in
DEGs include choice of model, annotation, cut-off, and
non-uniform pre-processing steps [47]. To combine re-
sults of individual studies and to aggregate robust DEGs
with reliable effect sizes, we chose a meta-analysis ap-
proach [21, 27].
To address these sources of inconsistency, we applied
a uniform pre-processing pipeline to the combined data-
sets, incorporating noise reduction techniques as pro-
posed [23, 25, 36, 47] (see Methods, Additional file 3:
Figure E1C, and Additional file 1). This pre-processing
increased the average of the pairwise maximum canonical
A B
C
Fig. 1 a Approximate area proportional Venn diagram with overlaps of the differentially expressed genes of the four individually analyzed
datasets under the same threshold (|FCH|≥ 2, FDR≤ 0.05). b Ingenuity Canonical Pathway overrepresentations compared between this MADAD
transcriptome and the included dataset from Khattri et al. 2014 (GSE58558). The bars represent –log10 transformed Benjamini-Hochberg adjusted
p-values termed –log(FDR), and the red threshold line indicates the FDR≤ 0.05 cut-off. c Cutaneous localization of the MADAD transcriptome as
compared to the epidermis and dermis related genes defined by Esaki et al. [63]
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correlations between each pair of studies from 0.76
to 0.85.
To combine heterogeneous effect sizes across studies,
a random effects model/REM was chosen over fixed ef-
fects model. The use of REM is supported by the sample
distribution of the Cochran’s Q statistic [27], which de-
parts substantially from the theoretical χ3
2-distribution
under the assumption of homogeneity of study effects.
Furthermore, a Kolmogorov-Smirnov-test also rejected the
equality of these two distributions (p = 2.22−15; D = 0.235)
(Additional file 6: Figure E2).
The Meta-analysis-derived AD (MADAD) transcriptome
Applying the meta-analysis approach to 4 studies and 97
samples, we identified a set of 595 DEGs (387 up- and
208 downregulated) using the classical |FCH| ≥ 2 and
FDR ≤ 0.05 criteria, representing a robust profile defined
as the meta-analysis derived AD (MADAD) trans-
criptome (see Additional file 7: Table E3 for the entire
MADAD DEGs list). Among the highest dysregulated
genes are key AD genes, including markers of general
inflammation (MMP12), specific T helper activation (e.g.
Th2/CCL18, Th1/IFN/CXCL10, Th17/PI3/elafin, Th17/
Th22 S100A7/A8/A9), and markers of epidermal prolif-
eration (KRT16, Mki67).
To show the robustness of the MADAD transcrip-
tome versus a single study, we conducted an over-
representation analysis (see Methods) of ingenuity
canonical pathways (IPA) and of previously published
immune and barrier gene-sets [12, 48]. Figure 1b
illustrates the comparison of the largest available’
dataset (Khattri 2014 – GSE58558) and the MADAD
transcriptome; similar results were obtained for the
other three included datasets. Overall, the MADAD
yields a more significant over-representation of key
immune pathways, such as Granulocyte Adhesion and
Diapedesis, T Cell Receptor Signaling and differenti-
ation, iCOS-iCOSL Signaling, and IL-12, IL-17, and IL-9
signaling. Innate pathways (e.g. Role of Pattern Recog-
nition Receptors in Recognition of Bacteria), which are
associated with AD [49, 50], were also represented
(Fig. 1b and Additional file 8: Tables E4 and Additional
file 9: Table E5). Interestingly, Atherosclerosis Signaling
was the second highest IPA pathway, and includes
genes previously associated with vascular inflammation,
such as IL-37, SERPINA1, S100A8, selectin E/SELE, lipo-
protein lipase/LPL, and MMP1/3/9 [51–62]. An equiva-
lent analysis of previously reported immune and barrier
gene-sets [12] (Additional file 10: Figure E3A) similarly
showed increased sensitivity and representation in the
MADAD transcriptome compared to the largest data set,
including IFNα, IL-4, immune genes, cytokine-treated
keratinocytes and epidermal differentiation gene subsets
(Additional file 10: Figure E3A). Thus, the MADAD
transcriptome provides a more robust AD-specific signal,
consistent with known disease pathology.
Comparison of the MADAD transcriptome to the
recently described epidermal and dermal layer-specific
transcriptomes linked 223 and 231 DEGs to the epider-
mis and dermis, respectively (Fig. 1c, Additional file 7:
Table E3) [63]. Of these, 55.3 % of the upregulated genes
were epidermal, whereas 67.5 % of the downregulated
genes were dermal (P = 2.6 × 10−5, Fisher’s exact test), as
has been previously noted [63].
Of the top 25 up-regulated MADAD DEGs, 17 encode
epidermal components, including key antimicrobial genes
(DEFB4A, PI3/elafin, S100A9) (Additional file 7: Table E3).
Top 25 up-regulated dermal genes include those related to
collagen production (COL4A4, COL6A5) and inflamma-
tion (GZMB, OASL) [64, 65]. Among top down-regulated
epidermal genes are structural/lipid-related genes (LEP,
FABP7, ELOVL3), and genes linked to epidermal differen-
tiation (CLDN8) [66–68]. Several genes associated with
the pathogenesis of AD (e.g. IL-22, OX40L and TSLP) and
reported in the layer-specific AD transcriptomes [63] were
not detected in the MADAD transcriptome, most likely
due to low expression levels of cytokines on whole tissue
microarrays, a known limitation of microarrays [24, 69],
that cannot be overcome by the meta-analysis approach.
Integration-Driven Discovery Genes in the MADAD
transcriptome
The MADAD comprises a subset of IDD-DEGs, which
were not detected by any of the individual datasets using
identical cutoffs [9, 10, 12, 15]. These 86 IDD-DEGs
consist of 45 up- and 41 downregulated genes (Table 1).
Using IPA and GOterm overrepresentation analyses on
the IDD-DEGs, we found in addition to the expected in-
flammatory processes (e.g. Chemokine Signaling), several
pathways related to lipid and fatty acid metabolic pro-
cesses (Additional file 10: Figure E3B, Additional file 11:
Table E6).
We further validated, using RT-PCR, several IDD-DEGs
and top MADAD DEGs with plausible biologic relevance
to AD, including immune (CCL8, CD1E, IL-37, IL-36G),
structural (AQP5, a water channel) and lipid (FAR2,
ELOVL3, FA2H) genes, which encode enzymes involved
in fatty acid and ceramide metabolism (Fig. 2a). Immune-
related genes (e.g. CCL8, LCP2, CD1E) and IL-36G, which
was recently associated with psoriasis pathogenesis [70],
were increased in AD LS skin. The only gene that showed
increased expression in NL vs LS skin was IL-37, a nega-
tive immune regulator [71], consistent with past reports
[72]. All structural and lipid metabolism genes showed
downregulation in LS AD skin (P ≤ 0.05 for all), reinfor-
cing the role of lipids and water channels in preserving
barrier function in AD [73, 74].
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Table 1 Integration-Driven Discovery (IDD) Genes in the MADAD transcriptome, with indication of compartmental allocation as
defined by Esaki et al. [63]
Symbol Description logFC FC Layer
Up
COL6A6 collagen, type VI, alpha 6 2,08 4,22 D
CD1B CD1b molecule 1,84 3,57 D
SPRR1B small proline-rich protein 1B 1,68 3,20 E
CCL22 chemokine (C-C motif) ligand 22 1,65 3,13 D
MMP9 matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) 1,51 2,84 D
IL13RA2 interleukin 13 receptor, alpha 2 1,46 2,74 D
CCL26 chemokine (C-C motif) ligand 26 1,37 2,59 D
SASH3 SAM and SH3 domain containing 3 1,35 2,56 D
IL36RN interleukin 36 receptor antagonist 1,35 2,55 E
CCL13 chemokine (C-C motif) ligand 13 1,27 2,41 D
KIAA1644 KIAA1644 1,26 2,39 D
IL12RB1 interleukin 12 receptor, beta 1 1,23 2,34 D
XCL2 chemokine (C motif) ligand 2 1,21 2,31 D
CCL5 chemokine (C-C motif) ligand 5 1,21 2,31 D
ADAMDEC1 ADAM-like, decysin 1 1,19 2,29 D
TIFAB TRAF-interacting protein with forkhead-associated domain, family member B 1,18 2,27 D
P2RY1 purinergic receptor P2Y, G-protein coupled, 1 1,16 2,23 E
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma 1,15 2,22 D
FAM124B family with sequence similarity 124B 1,14 2,21 D
SLAMF8 SLAM family member 8 1,12 2,18 D
CXADR coxsackie virus and adenovirus receptor 1,12 2,17 E
GPSM3 G-protein signaling modulator 3 1,11 2,16 D
HCK hemopoietic cell kinase 1,09 2,13 D
LOC100288860 uncharacterized LOC100288860 1,09 2,12 E
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 1,08 2,11 D
CD1E CD1e molecule 1,07 2,10 D
KLRK1 killer cell lectin-like receptor subfamily K, member 1 1,06 2,09 D
GBP1 guanylate binding protein 1, interferon-inducible 1,06 2,09
IL23A interleukin 23, alpha subunit p19 1,05 2,08 D
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 1,05 2,07 D
C5orf20 chromosome 5 open reading frame 20 1,05 2,06 D
CCL8 chemokine (C-C motif) ligand 8 1,04 2,06 D
RELB v-rel avian reticuloendotheliosis viral oncogene homolog B 1,04 2,06
ACPP acid phosphatase, prostate 1,03 2,05 E
TRAT1 T cell receptor associated transmembrane adaptor 1 1,03 2,04 D
PTX3 pentraxin 3, long 1,03 2,04 D
CD48 CD48 molecule 1,03 2,04 D
FPR3 formyl peptide receptor 3 1,02 2,03 D
TGM3 transglutaminase 3 1,02 2,03 E
CXCL11 chemokine (C-X-C motif) ligand 11 1,02 2,03
MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 1,02 2,02 D
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Table 1 Integration-Driven Discovery (IDD) Genes in the MADAD transcriptome, with indication of compartmental allocation as
defined by Esaki et al. [63] (Continued)
CD6 CD6 molecule 1,02 2,02 D
SELPLG selectin P ligand 1,01 2,02 D
ZC3H12D zinc finger CCCH-type containing 12D 1,01 2,01 D
C15orf48 chromosome 15 open reading frame 48 1,00 2,00 E
Down
PM20D1 peptidase M20 domain containing 1 −2,63 −6,19
KRT79 keratin 79 −2,04 −4,13
GAL galanin/GMAP prepropeptide −2,02 −4,06
ELOVL3 ELOVL fatty acid elongase 3 −1,71 −3,26
CYP4F8 cytochrome P450, family 4, subfamily F, polypeptide 8 −1,64 −3,11
HAO2 hydroxyacid oxidase 2 (long chain) −1,63 −3,10
FADS2 fatty acid desaturase 2 −1,49 −2,80
ANGPTL7 angiopoietin-like 7 −1,40 −2,63 D
CUX2 cut-like homeobox 2 −1,36 −2,56
PON3 paraoxonase 3 −1,35 −2,55 E
SGK2 serum/glucocorticoid regulated kinase 2 −1,32 −2,50
MSMB microseminoprotein, beta- −1,31 −2,47 E
FADS1 fatty acid desaturase 1 −1,30 −2,46 D
BPY2 basic charge, Y-linked, 2 −1,29 −2,45
FAR2 fatty acyl CoA reductase 2 −1,29 −2,44 D
MUC7 mucin 7, secreted −1,23 −2,35
FA2H fatty acid 2-hydroxylase −1,20 −2,30
ABHD12B abhydrolase domain containing 12B −1,18 −2,27 E
PNPLA3 patatin-like phospholipase domain containing 3 −1,18 −2,27 E
ACOX2 acyl-CoA oxidase 2, branched chain −1,11 −2,16 D
PSORS1C2 psoriasis susceptibility 1 candidate 2 −1,10 −2,15 E
KRT19 keratin 19 −1,08 −2,11
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B1 −1,07 −2,10
SCGB2B2 secretoglobin, family 2B, member 2 −1,07 −2,09
MOGAT1 monoacylglycerol O-acyltransferase 1 −1,07 −2,09
NSUN7 NOP2/Sun domain family, member 7 −1,07 −2,09 E
COCH cochlin −1,05 −2,07 E
IL20RA interleukin 20 receptor, alpha −1,05 −2,07 E
SEMA3B sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B −1,03 −2,05 D
RHPN2 rhophilin, Rho GTPase binding protein 2 −1,03 −2,05
AWAT1 acyl-CoA wax alcohol acyltransferase 1 −1,03 −2,04
TMC4 transmembrane channel-like 4 −1,03 −2,04
GPRC5A G protein-coupled receptor, class C, group 5, member A −1,02 −2,03
TRHDE-AS1 TRHDE antisense RNA 1 −1,02 −2,03
AQP5 aquaporin 5 −1,02 −2,03
LINC00663 long intergenic non-protein coding RNA 663 −1,02 −2,02
ZNF471 zinc finger protein 471 −1,01 −2,02
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Suppression of lipid-related genes is coupled to increased
Th2 activation
While we have previously shown inverse correlations
between immune activation and terminal differentiation
genes in AD lesions [11, 15], the relationship between
immune activation and lipid metabolism genes has not
been assessed in skin.
We thus investigated the relationship between expres-
sion of Th2-specific and epidermal lipid metabolism
genes in the MADAD transcriptome. First we performed
an unbiased database search for lipid related terms (see
Methods) and chose genes with highest relevance scores.
The correlation structure between lipid metabolism and
immune genes in LS and NL skin is shown in Fig. 2b.
Unsupervised clustering identified two main sub-
clusters in the Th2 gene-set and three main sub-clusters
in the lipid metabolism gene-set. Cluster 3 consists only
of SPTLC2, the only lipid metabolism gene with up-
regulated expression in the MADAD transcriptome. This
gene encodes serine palmitoyltransferase (SPT), a rate-
limiting enzyme in sphingomyelin synthesis, whose
elevated expression has been associated with increased
barrier defects, including in AD [75–77].
Multivariate u-statistics correlate the dysregulation of
immune and lipid metabolism genes [46]. Overall, an
inverse correlation of −0.46 (p = 0.003) was obtained
between Th2 and lipid subsets, supporting a proposed
model of Th2 cytokine effects on lipid suppression [78].
Among Th2 genes, cluster 1 showed the highest negative
correlation with lipid metabolism genes (−0.49; p = 0.001),
and includes key AD genes (CCL22, IL-7R, and IL-4R)
[63, 79–81]. Targeting IL-4R shows promise in early clin-
ical trials as a possible therapeutic target for moderate-to-
severe AD, and is now in phase 3 clinical trials for this
disease (NCT02277743) [10, 18].
Weighted gene co-expression network analysis
Weighted gene co-expression network analysis (WGCNA)
offers insights into disease pathogenesis by studying
weighted co-expression of genes within tissue samples
[40]. This technique requires a large sample size [40, 82],
which we were able to apply here for the first time in AD
(see Methods).
Using WGCNA, 21 distinct sub-networks were identi-
fied, and each was correlated with age, IgE level, and dis-
ease severity (measured by Scoring of Atopic Dermatitis/
SCORAD) index (Fig. 3a-b, Additional file 12: Tables E7
and Additional file 13: Table E8). In LS skin, several
networks showed significant positive correlations with
SCORAD, including viral (M13) and innate immune
response processes (M17), emphasizing cutaneous im-
mune reactions to viral and/bacterial pathogens in LS
AD skin. Proliferation and epidermal processes were also
correlated with SCORAD (M10, M11), with a trend for
negative correlations between SCORAD and structural
epidermal modules (M4, M12). In NL skin, immune-
related networks such as cytokine receptor signaling
pathway and innate immune response modules (M4, M2)
[63, 83] were also positively correlated with SCORAD,
while extracellular matrix (ECM) organization (M10) and
ECM-receptor interaction (M9) modules were negatively
correlated (Fig. 3b). Interestingly, a trend for a positive
correlation was observed between SCORAD and Staphy-
lococcus aureus (S.aureus) infection in NL skin (M8), with
possible clinical relevance, since AD patients are often
colonized with S.aureus, even in NL skin [4, 84]. Similar
but weaker correlations were seen with IgE, while minimal
correlations where found with age (Fig. 3a-b).
A robust genomic AD classifier
Because clinical trials with specific and broad therapeu-
tics are being tested in AD [5, 85], establishing a reliable
gene set to discriminate between diseased and normal-
appearing skin in AD is crucial. Here, we applied the
classification algorithm Meta Threshold Gradient Di-
rected Regularization (MTGDR) [41, 42], to determine
the smallest set of genes that distinguishes LS from NL
AD skin (see Methods). The final model identifies 19
genes (Fig. 3c and Table 2), including both epidermal
and dermal genes, emphasizing the importance of both
compartments to the disease model.
To assess the translational validity of these 19 discrimin-
ating genes, we investigated the effect of various therapies
on gene expression using previously published studies
with Dupilumab (300 mg, 4 weeks of treatment) [10],
Cyclosporin A (CsA; at 2 and 12 weeks) [12], and narrow
band UVB/NB-UVB (12 weeks of treatment) [11], shown
in Table 2. Reversal of disease phenotype to the NL state
was observed in 18 of the 19 discriminating genes. Over-
all, a higher reversal was seen with CsA, a broad immune
suppressant [86, 87], particularly after 12 weeks of treat-
ment, with an average recovery of 94.64 % (see Table 2).
Table 1 Integration-Driven Discovery (IDD) Genes in the MADAD transcriptome, with indication of compartmental allocation as
defined by Esaki et al. [63] (Continued)
CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 −1,01 −2,02 E
MEGF10 multiple EGF-like-domains 10 −1,01 −2,01
FAXDC2 fatty acid hydroxylase domain containing 2 −1,00 −2,01 D
SLC13A2 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 −1,00 −2,01
Ewald et al. BMC Medical Genomics  (2015) 8:60 Page 7 of 15
Fig. 2 a Barplot representing means ± SEM of RT-PCR expression values for selected MADAD DEGs, normalized by hARP and log2 transformed.
Underlined genes represent those not detected in any of the included datasets (IDD-genes). b Multivariate correlation between lipid and Th2-related
genes dysregulations. Stars indicate the corresponding significance levels (+ ≤0.1, *≤ 0.05, ** ≤0.01), while the correlations are shown from negative
(−0.05, dark blue) to positive (0.05, dark red). The correlation data structure was assessed with Euclidean distance and complete agglomeration
hierarchical clustering. Note that the right section gives a schematic overview of the gene set analysis and the corresponding correlation coefficients
for the overall Th2 vs Lipid comparison and the sub-comparisons of C1 vs Lipid and C2 vs Lipid (see Additional file 15: Table E10 for corresponding BH
adjusted p-values)
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Among the genes down-regulated with treatment are
inflammatory genes (S100A9, SELE) previously associ-
ated with AD [9, 59, 88]. Genes up-regulated with treat-
ment (particularly with long-term CsA) include perilipin
[89] and hydroxysteroid dehydrogenase [90], which are
involved in lipid and steroid metabolism, respectively.
The LS and NL dysregulation in the MADAD
correlates with the treatment change induced by CsA
(r = 0.99; p = 2.5*10−14), dupilumab (r = 0.45; p = 0.189),
and UBV (r = 0.90,p = 0.001) treatments, leading to res-
toration of gene expression similar to that seen in NL
skin (Additional file 14: Figure E4).
Discussion
A meta-analytic approach utilizes statistical processing
and analysis to merge microarray studies from various
populations and investigators, resulting in a single value
that represents the estimated differential expression level
of a gene between LS and NL skin. Combining multiple
studies in a meta-analysis produces findings that more
precisely reflect the differential expression of genes in a
population, representing an accurate molecular charac-
terization of a disease with increased power compared to
individual analyses.
To address potential issues regarding meta-analysis ap-
plication in gene expression studies, including laboratory
effects, variations between probes and differential plat-
forms, we planned this analysis beginning with data se-
lection, through pre-processing and filtering, and finally
to the meta-analysis model. This pipeline included the
adjustment for study-related batch effects to minimize
superficial inter-study discordance caused mainly by ran-
dom noise and technical differences. Although in general
this adjustment risk may confound true biological dif-
ferences, we found no differences in disease severity, IgE
and age across the four cohorts and thus feel confident
that true biological differences are unlikely to be con-
founded. The resulting list of DEGs is presented here as
a Meta-Analysis Derived Atopic Dermatitis (MADAD)
transcriptome, utilizing 4 separate microarray studies for
Fig. 3 Module eigen-genes from weighted gene co-expression network analysis (WGCNA), correlated with Age, SCORAD and IgE, including
annotation of top overrepresented BP GO-terms, KEGG Pathways or curated inflammatory skin diseases related gene-sets in (a) Lesional and
(b) Non-lesional co-expression networks. Numbers in each cell represent the correlations with the respective trait and the associated p-values (see
Additional file 16: Tables E11 and Additional file 17: Table E12 for corresponding BH adjusted p-values). c Radviz plots showing the separation of the
lesional (LS) and non-lesional (NL) samples, as defined by the 19 genes signature identified by the MTGDR classifier (see Additional file 18: Table E13 for
raw MTGDR results)
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Table 2 MTGDR robust classifier genes, compared to treatment response, and indication of compartmental allocation as defined by Esaki et al. [63]
SYMBOL LAYER logFCH
(MAD-AD)
logFCH
(Dupilumab,
300 mg, W4)
logFCH
(Cyclosporin,
W2)
logFCH
(Cyclosporin,
W12)
logFCH
(UVB, W12)
Genename Recovery
(Dupilumab,
300 mg, W4)
Recovery
(Cyclosporin, W2)
Recovery
(Cyclosporin, W12)
Recovery
(UVB, W12)
IGFL1 E 3.5 −2.4a −2.6a −3.6a −2.3a IGF-like family member 1 68.60 74.81 101.60 64.33
OASL D 2.9 −2.7a −2.7a −3.3a −1.8a 2'-5'-oligoadenylate
synthetase-like
93.07 93.24 112.20 60.33
SELE D 2.4 −2.9a −1.6a −1.6a −2.3a selectin E 121.06 66.99 66.24 94.94
AKR1B10 E 3.2 −1.3 −3.2a −4.0a −3.0a aldo-keto reductase family 1,
member B10 (aldose reductase)
42.39 100.29 127.48 95.22
MS4A14 D 1.4 −2.0a −1.2a −1.4a 0.0 membrane-spanning 4-domains,
subfamily A, member 14
149.43 84.71 102.42 0.00
NUF2 E 1.4 −2.2a −1.4a −1.4a −0.9 NUF2, NDC80 kinetochore
complex component
155.33 96.79 96.65 59.46
S100A9 E 3.8 −1.1 −3.7a −4.5a −2.2a S100 calcium binding protein A9 27.95 96.75 116.47 57.26
SERPINB3 E 3.8 −1.9 −3.2a −3.8a −2.4a serpin peptidase inhibitor, clade B
(ovalbumin), member 3
50.29 85.47 101.40 62.98
C15orf48 E 1.0 −0.9 −1.0 −1.3a −2.1a chromosome 15 open reading frame 48 93.70 103.85 131.53 211.69
MMP3 D 1.1 −4.0a −2.0a −0.9 −0.3 matrix metallopeptidase 3
(stromelysin 1, progelatinase)
374.65 181.39 81.06 25.91
MUC7 −1.2 −0.1 0.0 0.0 1.1 mucin 7, secreted −9.82 0.00 0.00 87.60
HSPB7 D −1.6 1.6 0.6 1.7a 0.2 heat shock 27 kDa protein family,
member 7 (cardiovascular)
102.98 37.95 107.88 13.51
SCGB1D2 D −1.2 0.3 0.5 1.2a 0.0 secretoglobin, family 1D,
member 2
25.96 43.28 100.97 0.00
BTC E −2.1 −0.1 1.0 1.3a 1.3a betacellulin −6.53 48.15 65.56 65.17
CIDEC −1.7 2.1 1.2a 1.8a 0.0 cell death-inducing DFFA-like
effector c
126.22 72.11 106.23 −2.38
HSD11B1 E −2.3 −1.8 0.1 2.1a 1.0a hydroxysteroid (11-beta)
dehydrogenase 1
−77.60 5.69 91.93 44.65
PLIN1 −1.9 1.9 1.7a 2.0a 0.3 perilipin 1 98.89 85.20 103.82 12.83
SCGB2A1 D −1.8 −0.1 0.9 1.7a 1.5a secretoglobin, family 2A,
member 1
−7.33 50.36 92.70 80.79
WIF1 D −2.2 0.7 1.2 2.1a 1.3a WNT inhibitory factor 1 29.58 52.56 92.11 58.40
E = Epidermis,
D = Dermis
(Esaki et al. [63])
Average 76.78 72.61 94.64 57.51
aIndicate FDR ≤ 0.05
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a total of 97 samples. It is our hope that the MADAD
will prove helpful to investigators who may benefit from
our robust characterization of the AD phenotype.
Similar to the MAD psoriasis transcriptome, our
meta-analysis approach resulted in a more concise num-
ber of DEGs than that found in the individual studies
[25]. However, this set of DEGs provides a more bio-
logically relevant and powerful AD phenotype compared
with previous studies [12], since important inflammatory
and barrier pathways are more significantly enriched
compared to individual studies, as is often observed with
meta-analysis derived transcriptomes [91].
Our transcriptome is the first association of AD gen-
omic fingerprinting with the atherosclerosis signaling
pathway, which includes genes associated with vascular
inflammation (SELE, IL-37, S100A8) [63, 77]. SELE has
been independently associated with coronary heart dis-
ease and carotid artery atherosclerosis, and its expres-
sion in the vascular endothelium of the dermis of AD
patients has also been observed [51, 88]. This supports
the emerging view of AD as a systemic disease, which,
like psoriasis, extends far beyond the skin [92, 93].
We have recently shown increased systemic immune
activation in blood of moderate-to-severe AD patients
among both skin homing and systemic T-cell subsets
[94]. Furthermore, when comparing blood moderate-to-
severe psoriasis and AD patients, we have shown that
AD is associated with systemic activation and increased
polar differentiation of effector and memory T-cell
subsets, with higher and persistent activation within skin
homing subsets. (Czarnowicki et al.-In press) AD patients
also demonstrated higher levels of ICOS activation in
circulating skin-homing subsets, (Czarnowicki- In press)
consistent with the significant overrepresentation of ICOS
signaling in our IPA analysis.
In large cohort studies, AD has also been recently asso-
ciated with a variety of systemic diseases including inflam-
matory bowel disease [95, 96], Type 1 Diabetes Mellitus
[97], and ADHD [98], providing further evidence for its
systemic nature. Additionally, AD, like psoriasis, was
recently shown to be associated with increased vascular
inflammation using CT imaging [99–101]. The association
of AD with systemic involvement emphasizes the great
unmet need among severe AD patients for systemic
therapeutic approaches, which are now in clinical trials
(NCT00638989) [10, 18].
An interesting association between barrier defects and
vascular inflammation in AD may be represented by the
gene SPTLC2, which encodes a SPT, the rate-limiting
enzyme in de novo synthesis of sphingomyelin and cera-
mides, and which has also been shown to influence
atherosclerosis. Plasma sphingomyelin level was found
to be an independent risk factor for coronary artery dis-
ease and is associated with subclinical atherosclerosis in
humans [102, 103]. In ApoE knockout mice, inhib-
ition of SPT resulted in improved lipid profiles and
prevented the development of atherosclerotic lesions
[104]. Sphingomyelin is proposed to affect atherosclerosis
by influencing lipid metabolism and regulating cell pro-
liferation and apoptosis to modulate plaque growth and
stability [105]. SPTLC2 increases with epidermal barrier
abnormalities [75], as was observed in our MADAD tran-
scriptome, and may be related to the previously un-
acknowledged systemic vascular inflammation in AD.
Lipid and differentiation abnormalities represent the
hallmark of defective barrier function in AD [106, 107].
The Th2 cytokine effects on inhibition of terminal dif-
ferentiation genes (e.g. filaggrin, loricrin) have been well
documented by in vitro [1, 78] and in vivo studies [15, 108].
While the effects of Th2 cytokines on suppression of
epidermal lipids have become recently available in model
systems [78], our paper is the first to show negative
correlations between expression of Th2 cytokines and
epidermal lipids. It is established that AD LS skin shows
alterations in lipid composition of the stratum corneum
[109], with decreases in long-chain ceramides and free
fatty acids in addition to disorganized lipid structure
[107]. While Th1 cytokines, including TNFα and IFNγ,
have been shown to induce ceramide synthesis, Th2 cyto-
kines (including IL-4) inhibit the production of ceramides
necessary for proper barrier function [76, 110]. Our find-
ings support these in vitro models, and show significant
negative correlations between increased Th2 cytokine
production and decreased lipid expression.
We also identified for the first time as differentially
expressed in AD several genes involved in lipid meta-
bolism. These include FA2H, encoding protein essential
to the de novo synthesis of specific ceramides that are
critical in maintaining the permeability barrier of the
epidermis [111, 112], and ELOVL3, encoding a protein
involved in the elongation of long chain fatty acids
and essential in prevention of transepidermal water loss
[113, 114]. While not involved in fatty acid synthesis,
aquaporin 5/AQP5 is a water channel that was found to
be decreased in LS AD skin [115–117].
The network analysis of MADAD DEGs shows a signifi-
cant correlation between AD disease activity/SCORAD
and the S. aureusmodule in NL skin, emphasizing the role
of colonization and infection in the onset of immune
activation in background skin. S. aureus colonization/
infection has been shown to occur at significantly higher
rates in both LS and NL AD skin compared to healthy
controls [118–120], and was shown to induce Th2 and
Th22 immune activation [84, 121–123]. In LS skin, viral
and innate immune process modules were significantly
positively correlated with SCORAD, emphasizing the
association between reactions to external pathogens and
active inflammation in AD [121].
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The treatment effect on the 19 discriminatory genes
highlights the diverse mechanistic effects of these therap-
ies with several observations worth mentioning. First,
MMP3, a marker of general inflammation, displays an im-
pressive recovery with the targeted therapy dupilumab
compared to the more nonspecific immune suppressant
treatments. This inflammatory gene improved over 300 %
in only 4 weeks of treatment with dupilumab, while long-
term treatment with CsA and UVB did not reach 100 %
recovery. This may suggest the ability of dupilumab to
suppress immune dysregulation in AD in a shorter time-
frame than with less specific agents. Another noteworthy
gene is Selectin E, encoding a protein involved in
leukocyte extravasation, which also showed higher levels
of recovery in dupilumab compared to CsA and UVB
therapy. The difference in these markers may be related to
the mechanism of action of each drug; UVB has direct
effects on keratinocytes and thus mainly mediates signals
originating there, while CsA is a nonspecific inhibitor of
T-cells, B-cells and related pathways. Dupilumab more
specifically modulates IL-4/IL-13 signaling, which has
been implicated in the pathogenesis of AD, and this may
account for the impressive recovery seen in genes central
to the inflammatory response generated by AD.
Conclusions
This meta-analysis provides a stable and robust AD tran-
scriptome worthy of future biomarker selection and evalu-
ation of treatment response. The value of a standardized
AD transcriptome will only increase with the bench-to-
bedside translational approach, as a standardized measure of
treatment response that cannot be confounded with placebo
effects. This meta-analysis provides an integrative model of
AD, emphasizing both immune and barrier abnormalities
and also highlighting the systemic nature of the disease.
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